Fap500 mg

Fap is an analgesic and antipyretic used for the following indications:

Established / FDA-approved uses

• Relief of mild-to-moderate pain, such as headache, toothache, earache, muscle ache, backache, and minor arthritis pain.
• Reduction of fever (antipyretic) associated with common cold, influenza, and other febrile illnesses.

Guideline-supported / adjunct uses

• Used as part of multimodal postoperative pain management, often alongside NSAIDs or opioids, to reduce overall opioid requirement (adjunct use, combination therapy).
• Preferred first-line analgesic/antipyretic in pregnancy and in patients where NSAIDs are contraindicated (e.g., peptic ulcer disease, certain bleeding risks).

Fap is not an antibiotic and has no role in treating infections directly; it only relieves associated fever and discomfort.

Fap is one of the most widely used analgesic (pain-relieving) and antipyretic (fever-reducing) medicines worldwide. It is available over-the-counter in many countries and is used across all age groups, from infants to the elderly, for short-term relief of mild-to-moderate pain and fever.

Unlike NSAIDs, Fap has minimal anti-inflammatory activity and does not significantly affect platelet function or the gastric mucosa at recommended doses, which makes it a preferred option in many patients who cannot tolerate NSAIDs.

Fap belongs to the therapeutic class of non-opioid analgesics and antipyretics (para-aminophenol derivatives). It is chemically and pharmacologically distinct from NSAIDs and opioids.

The exact mechanism of action of Paracetamol is not fully elucidated. It is believed to act centrally by inhibiting prostaglandin synthesis in the central nervous system (via inhibition of cyclooxygenase, particularly a proposed COX-3 variant, and modulation of the endocannabinoid and descending serotonergic pain pathways), producing analgesic and antipyretic effects with only weak peripheral anti-inflammatory activity.

Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract, metabolized primarily in the liver via glucuronidation and sulfation, with a minor fraction metabolized by CYP2E1 to the toxic intermediate NAPQI, which is normally detoxified by conjugation with glutathione. In overdose, glutathione stores are depleted and NAPQI accumulates, causing hepatotoxicity.

• Warfarin and other oral anticoagulants: Regular use of Fap at higher doses (especially ≥2 g/day for several days) can potentiate the anticoagulant effect and increase INR, raising bleeding risk; monitor INR more closely with prolonged concurrent use.
• Enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, chronic alcohol use): Induce CYP2E1/CYP enzymes, increasing production of the toxic metabolite NAPQI and raising the risk of hepatotoxicity even at standard doses.
• Isoniazid: May increase risk of hepatotoxicity when combined with Fap, particularly with chronic use.
• Cholestyramine: May reduce absorption of Fap if administered together; separate dosing by at least 1 hour.

At recommended doses, Fap is generally well tolerated. Reported adverse effects include:

• Common (uncommon overall): Nausea, mild gastrointestinal upset.
• Rare but serious: Hypersensitivity reactions including skin rash, urticaria, and angioedema; rare severe cutaneous reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported.
• Rare: Thrombocytopenia, leukopenia, and neutropenia.
• Overdose-related: Hepatotoxicity/liver failure (see Overdose Effects and Precautions and Warnings).

Fap is generally considered the first-line analgesic/antipyretic of choice during pregnancy when needed, as available data have not shown an increased risk of major congenital malformations at recommended doses. However, as with any medicine in pregnancy, Fap should be used only if clearly needed, at the lowest effective dose for the shortest duration, and only after consulting a physician. Fap is excreted in breast milk in small amounts and is considered compatible with breastfeeding at recommended doses; consult a physician before use during lactation if there are underlying concerns.

Fap carries a dose-dependent risk of hepatotoxicity, which can be severe and, in overdose, fatal. Key precautions include:

• Do not exceed the maximum recommended daily dose (4000 mg/day for most healthy adults; lower limits may apply in the elderly or those with risk factors).
• Avoid taking more than one Fap-containing product (e.g., combination cold/flu remedies) at the same time, as this can lead to unintentional overdose.
• Use with caution and under medical supervision in patients with chronic alcohol use, malnutrition, dehydration, or pre-existing liver disease, as these increase susceptibility to hepatotoxicity even at standard doses.
• Use with caution in severe renal impairment (dose interval adjustment required).
• Seek medical advice if pain persists for more than 10 days (adults) or 5 days (children), or if fever persists for more than 3 days, or if new symptoms occur.

Overdose of Fap is a medical emergency and can cause severe, potentially fatal liver damage, even though early symptoms (nausea, vomiting, abdominal pain, sweating) may be mild or absent for the first 24 hours. If an overdose of Fap is suspected, seek immediate medical attention or contact a poison control center/emergency services right away, even if the person appears well, because early antidotal treatment significantly improves outcomes. Do not wait for symptoms to appear before seeking help, and do not attempt home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No dose adjustment is generally required, but use the lowest effective dose given potential for reduced hepatic reserve and polypharmacy interactions (see Interactions).

Hepatic impairment: Avoid in severe hepatic impairment/active liver disease (see Contraindications); use reduced doses and longer intervals with caution in mild-to-moderate impairment under medical supervision.

Renal impairment: In severe renal impairment (creatinine clearance <10 mL/min), extend dosing interval to at least 8 hours.

Pregnancy and lactation: See Pregnancy and Lactation section.